Cargando…

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy

Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft‐versus‐host disease and cytokine release syndrome, therapy resistance, limited sources, as well as high cost, limited the appli...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yan, Jin, Shengjie, Zhuang, Qiqi, Liu, Na, Chen, Ruyi, Adam, Sofia Abdulkadir, Jin, Jie, Sun, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691297/
https://www.ncbi.nlm.nih.gov/pubmed/38045827
http://dx.doi.org/10.1002/mco2.422
_version_ 1785152710933217280
author Wang, Yan
Jin, Shengjie
Zhuang, Qiqi
Liu, Na
Chen, Ruyi
Adam, Sofia Abdulkadir
Jin, Jie
Sun, Jie
author_facet Wang, Yan
Jin, Shengjie
Zhuang, Qiqi
Liu, Na
Chen, Ruyi
Adam, Sofia Abdulkadir
Jin, Jie
Sun, Jie
author_sort Wang, Yan
collection PubMed
description Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft‐versus‐host disease and cytokine release syndrome, therapy resistance, limited sources, as well as high cost, limited the application of CAR T cells. Recently, CAR natural killer (NK) cells have been pursued as the effector cells for adoptive immunotherapy for their attractive merits of strong intrinsic antitumor activity and relatively mild side effects. Additionally, CAR NK cells can be available from various sources and do not require strict human leukocyte antigen matching, which suggests them as promising “off‐the‐shelf” products for clinical application. Although the use of CAR NK cells is restrained by the limited proliferation and impaired efficiency within the immunosuppressive tumor microenvironment, further investigation in optimizing CAR structure and combination therapies will overcome these challenges. This review will summarize the advancement of CAR NK cells, CAR NK cell manufacture, the clinical outcomes of CAR NK therapy, the challenges in the field, and prospective solutions. Besides, we will discuss the emerging application of other immune cells for CAR engineering. Collectively, this comprehensive review will provide a valuable and informative summary of current progress and evaluate challenges and future opportunities of CAR NK cells in tumor treatment.
format Online
Article
Text
id pubmed-10691297
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106912972023-12-02 Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy Wang, Yan Jin, Shengjie Zhuang, Qiqi Liu, Na Chen, Ruyi Adam, Sofia Abdulkadir Jin, Jie Sun, Jie MedComm (2020) Reviews Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft‐versus‐host disease and cytokine release syndrome, therapy resistance, limited sources, as well as high cost, limited the application of CAR T cells. Recently, CAR natural killer (NK) cells have been pursued as the effector cells for adoptive immunotherapy for their attractive merits of strong intrinsic antitumor activity and relatively mild side effects. Additionally, CAR NK cells can be available from various sources and do not require strict human leukocyte antigen matching, which suggests them as promising “off‐the‐shelf” products for clinical application. Although the use of CAR NK cells is restrained by the limited proliferation and impaired efficiency within the immunosuppressive tumor microenvironment, further investigation in optimizing CAR structure and combination therapies will overcome these challenges. This review will summarize the advancement of CAR NK cells, CAR NK cell manufacture, the clinical outcomes of CAR NK therapy, the challenges in the field, and prospective solutions. Besides, we will discuss the emerging application of other immune cells for CAR engineering. Collectively, this comprehensive review will provide a valuable and informative summary of current progress and evaluate challenges and future opportunities of CAR NK cells in tumor treatment. John Wiley and Sons Inc. 2023-12-01 /pmc/articles/PMC10691297/ /pubmed/38045827 http://dx.doi.org/10.1002/mco2.422 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Wang, Yan
Jin, Shengjie
Zhuang, Qiqi
Liu, Na
Chen, Ruyi
Adam, Sofia Abdulkadir
Jin, Jie
Sun, Jie
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
title Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
title_full Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
title_fullStr Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
title_full_unstemmed Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
title_short Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
title_sort chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691297/
https://www.ncbi.nlm.nih.gov/pubmed/38045827
http://dx.doi.org/10.1002/mco2.422
work_keys_str_mv AT wangyan chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy
AT jinshengjie chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy
AT zhuangqiqi chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy
AT liuna chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy
AT chenruyi chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy
AT adamsofiaabdulkadir chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy
AT jinjie chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy
AT sunjie chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy